Follow-Up of Patients With Relapsed/Refractory FLT3 Mutation–Positive AML Treated With Gilteritinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Blood 2022 Jan 26;[EPub Ahead of Print], AE Perl, RA Larson, NA Podoltsev, SA Strickland, ES Wang, E Atallah, GJ Schiller, G Martinelli, A Neubauer, J Sierra, P Montesinos, C Récher, SS Yoon, N Hosono, M Onozawa, S Chiba, HJ Kim, N Hasabou, Q Lu, R Tiu, MJ LevisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.